<p>Research Progress Evaluating the Function and Mechanism of Anti-Tumor Peptides</p>

Abstract

Malignant tumors cause a high mortality rate worldwide, and they severely threaten human health and negatively affect the economy. Despite the advancements in tumor-related molecular genetics and effective new processes in anti-tumor drug development, the anti-tumor drugs currently used in clinical practice are inadequate due to their poor efficacy or severe side effects. Therefore, developing new safe and efficient drugs is a top priority for curing cancer. The peptide has become a suitable agent due to its exact molecular weight between whole protein and small molecule, and it has high targeting ability, high penetrability, low immunogenicity, and is convenient to synthesize and easy to modify. Because of these advantages, peptides have excellent prospect for application as anti-tumor agents. This article reviews the recent research progress evaluating anti-tumor peptides and their anti-tumor mechanisms, and may act as a reference for the future development and clinical application of anti-tumor peptides.

Peptidome characterization of ovarian cancer serum and the identification of tumor suppressive peptide ZYX36-58

“…Then we found that the activation of a variety of proteins depends on proteolytic processes. As a product of the proteolytic products, endogenous peptides can also directly interact with target cells or target proteins and thus regulate the targets' function (2). Indeed, most of the peptides' function was closely related with their precursor proteins (2).…”

“…As a product of the proteolytic products, endogenous peptides can also directly interact with target cells or target proteins and thus regulate the targets' function (2). Indeed, most of the peptides' function was closely related with their precursor proteins (2). So gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of the precursor proteins of the differentially expressed peptides were performed.…”

“…Due to the small molecular weight, short half-life, high targeting efficiency, low immunogenicity, peptides have been considered as promising drugs for the treatment of diseases (2). For example, ALM201, a therapeutic peptide derived from FKBPL, could disrupt angiogenesis and inhibit self-renewal of cancer stem cells and thus inhibit ovarian cancer growth, and has completed a Phase Ia clinical trial in ovarian cancer patients (3).…”

Anti-cancer peptides: classification, mechanism of action, reconstruction and modification

“…As of November 2019, more than 20 ACPs have been approved by FDA and EMA. ACPs like Kyprolis, SomaKit TOC, Lutathera and Gallium Dotatoc Ga68 have been marketed in recent years [ 16 ]. Collectively, ACPs represent a promising alternative to conventional chemotherapy.…”

“…Coupled with the merits of relatively high tissue penetration and low occurrence of drug resistance, the clinical application prospect of ACPs are promising. A search of the US National Institutes of Health Clinical Trials database (https://clinicaltrials.gov/) using the phrase 'anti-cancer peptides' found 1002 peptide-based clinical trials that targeted different types of cancer [16]. For example, Bryostatin 1, one of the most abundant and best-studied peptides of the bryostatin family, has shown anti-tumour activity in Phase I trials in patients with malignant melanoma, lymphoma and ovarian carcinoma [17,18].…”